FDA Purple Book · Reference family
clesrovimab-cfor (Enflonsia)
clesrovimab-cfor is an FDA-licensed reference biologic from Merck Sharp & Dohme LLC. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2025
Reference approved
Reference product
351(a)BLA 761432
Enflonsia clesrovimab-cfor
Merck Sharp & Dohme LLC
- Approved
- Jun 09, 2025
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for clesrovimab-cfor, in chronological order.
Reference approval
Approval date of the reference clesrovimab-cfor product.
1 yr ago
Frequently asked questions
Are there biosimilars approved for clesrovimab-cfor (Enflonsia)?
No 351(k) biosimilars or interchangeable biosimilars referencing clesrovimab-cfor are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.